TScan Therapeutics’ (TCRX) “Outperform” Rating Reiterated at Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a research note issued on Tuesday, Benzinga reports. They presently have a $10.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 35.50% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 7th.

TScan Therapeutics Stock Up 1.7 %

Shares of NASDAQ TCRX opened at $7.38 on Tuesday. The stock has a market capitalization of $353.35 million, a P/E ratio of -3.90 and a beta of 0.90. The company has a 50-day moving average price of $7.14 and a 200-day moving average price of $5.78. TScan Therapeutics has a 1 year low of $1.62 and a 1 year high of $9.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.51 and a quick ratio of 6.51.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The business had revenue of $7.21 million during the quarter, compared to the consensus estimate of $2.94 million. On average, equities research analysts forecast that TScan Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently made changes to their positions in TCRX. Pale Fire Capital SE purchased a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $42,000. Letko Brosseau & Associates Inc. purchased a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $83,000. Cannon Global Investment Management LLC purchased a new stake in TScan Therapeutics in the 1st quarter worth about $139,000. Finally, abrdn plc purchased a new stake in TScan Therapeutics in the 4th quarter worth about $1,166,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.